U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07826949) titled 'A Phase 1 Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma.' on Sept. 10.
Brief Summary: SRN-101 is designed to destroys tumor cells while simultaneously activating the immune system to fight cancer. This is a first in human, single arm study to evaluate SRN-101 for the treatment of adults with recurrent high-grade glioma (rHGG) who are eligible for resection.
Study Start Date: Oct. 15
Study Type: INTERVENTIONAL
Condition:
Recurrent High-Grade Gliomas
Brain Neoplasm
Glioma
Intervention:
DRUG: SRN-101
Given Intratumoral
PROCEDURE: Blood Specimen Collection
Perform blood wo...